Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.
Comparative effectiveness of BNT162b2 versus mRNA-1273 covid-19 vaccine boosting in England: matched cohort study in OpenSAFELY-TPP.
复制标题
DOI：
10.1136/bmj-2022-072808
复制
发表时间：
2023-03-15
影响因子：
105.7
通讯作者：
Sterne, Jonathan A. C.
中科院分区：
文献类型：
--
作者：
Hulme, William J.;Horne, Elsie M. F.;Parker, Edward P. K.;Keogh, Ruth H.;Williamson, Elizabeth J.;Walker, Venexia;Palmer, Tom M.;Curtis, Helen J.;Walker, Alex J.;Andrews, Colm D.;Mehrkar, Amir;Morley, Jessica;MacKenna, Brian;Bacon, Sebastian C. J.;Goldacre, Ben;Hernan, Miguel A.;Sterne, Jonathan A. C.
比较英国加强计划期间BNT162b2 mRNA（辉瑞- biontech）和mRNA-1273 (Moderna) covid-19疫苗的有效性。配对队列研究，模拟比较有效性试验。opensafety - tpp研究平台提供了相关的初级保健、医院和covid-19监测记录，涵盖了SARS-CoV-2三角洲和组粒变体占主导地位的时期。作为英格兰国家加强计划的一部分，在2021年10月29日至2022年2月25日期间接受了任一疫苗加强剂量的3 237 918名成年人，并接受了BNT162b2或ChAdOx1的初级疗程。接种BNT162b2或mRNA-1273作为加强疫苗剂量。接种加强剂后20周记录SARS-CoV-2阳性检测、covid-19相关住院、covid-19相关死亡和非covid-19相关死亡。每个疫苗组匹配了1 618 959人，总共随访64 546 391人周。BNT162b2阳性的20周风险为164.2(95%可信区间为163.3 - 165.1)，mRNA-1273阳性的20周风险为159.9 (159.0 - 160.8)；mRNA-1273与BNT162b2的风险比为0.95（95%可信区间0.95 ~ 0.96）。BNT162b2和mRNA-1273的20周风险分别为0.75（0.71 - 0.79）和0.65 (0.61 - 0.69)；风险比为0.89（0.82 ~ 0.95）。与Covid-19相关的死亡很少：BNT162b2的20周风险为0.028(0.021至0.037)，mRNA-1273的风险为0.024(0.018至0.033)；风险比0.83（0.58 ~ 1.19）。在由主要病程、疫苗品牌、年龄、既往SARS-CoV-2感染和临床易感性定义的亚组中，比较有效性大致相似。在δ变异和组粒变异时代分别比较疫苗的相对获益相似。这项对成人进行的匹配观察性研究估计，与BNT162b2相比，mRNA-1273加强疫苗接种在预防SARS-CoV-2阳性检测和预防接种后20周（随后是组粒变异优势期）的covid-19住院方面有适度的益处。
To compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during the booster programme in England. Matched cohort study, emulating a comparative effectiveness trial. Linked primary care, hospital, and covid-19 surveillance records available within the OpenSAFELY-TPP research platform, covering a period when the SARS-CoV-2 delta and omicron variants were dominant. 3 237 918 adults who received a booster dose of either vaccine between 29 October 2021 and 25 February 2022 as part of the national booster programme in England and who received a primary course of BNT162b2 or ChAdOx1. Vaccination with either BNT162b2 or mRNA-1273 as a booster vaccine dose. Recorded SARS-CoV-2 positive test, covid-19 related hospital admission, covid-19 related death, and non-covid-19 related death at 20 weeks after receipt of the booster dose. 1 618 959 people were matched in each vaccine group, contributing a total 64 546 391 person weeks of follow-up. The 20 week risks per 1000 for a positive SARS-CoV-2 test were 164.2 (95% confidence interval 163.3 to 165.1) for BNT162b2 and 159.9 (159.0 to 160.8) for mRNA-1273; the hazard ratio comparing mRNA-1273 with BNT162b2 was 0.95 (95% confidence interval 0.95 to 0.96). The 20 week risks per 1000 for hospital admission with covid-19 were 0.75 (0.71 to 0.79) for BNT162b2 and 0.65 (0.61 to 0.69) for mRNA-1273; the hazard ratio was 0.89 (0.82 to 0.95). Covid-19 related deaths were rare: the 20 week risks per 1000 were 0.028 (0.021 to 0.037) for BNT162b2 and 0.024 (0.018 to 0.033) for mRNA-1273; hazard ratio 0.83 (0.58 to 1.19). Comparative effectiveness was generally similar within subgroups defined by the primary course vaccine brand, age, previous SARS-CoV-2 infection, and clinical vulnerability. Relative benefit was similar when vaccines were compared separately in the delta and omicron variant eras. This matched observational study of adults estimated a modest benefit of booster vaccination with mRNA-1273 compared with BNT162b2 in preventing positive SARS-CoV-2 tests and hospital admission with covid-19 20 weeks after vaccination, during a period of delta followed by omicron variant dominance.
登录
查看更多内容
DOI：
10.1097/ede.0b013e3181d61eeb
发表时间：
2010-05
期刊：
Epidemiology (Cambridge, Mass.)
影响因子：
--
作者：
Lipsitch M;Tchetgen Tchetgen E;Cohen T
通讯作者：
Cohen T
影响因子：
82.9
作者：
Andrews, Nick;Stowe, Julia;Kirsebom, Freja;Toffa, Samuel;Sachdeva, Ruchira;Gower, Charlotte;Ramsay, Mary;Bernal, Jamie Lopez
通讯作者：
Bernal, Jamie Lopez
DOI：
10.1056/nejmoa2115463
发表时间：
2022-01-13
期刊：
The New England journal of medicine
影响因子：
--
作者：
Dickerman BA;Gerlovin H;Madenci AL;Kurgansky KE;Ferolito BR;Figueroa Muñiz MJ;Gagnon DR;Gaziano JM;Cho K;Casas JP;Hernán MA
通讯作者：
Hernán MA
影响因子：
39
作者：
Dickerman, Barbra A.;Madenci, Arin L.;Hernan, Miguel A.
通讯作者：
Hernan, Miguel A.
DOI：
10.1056/nejmoa2116414
发表时间：
2022-03-17
期刊：
The New England journal of medicine
影响因子：
--
作者：
Atmar RL;Lyke KE;Deming ME;Jackson LA;Branche AR;El Sahly HM;Rostad CA;Martin JM;Johnston C;Rupp RE;Mulligan MJ;Brady RC;Frenck RW Jr;Bäcker M;Kottkamp AC;Babu TM;Rajakumar K;Edupuganti S;Dobrzynski D;Coler RN;Posavad CM;Archer JI;Crandon S;Nayak SU;Szydlo D;Zemanek JA;Dominguez Islas CP;Brown ER;Suthar MS;McElrath MJ;McDermott AB;O'Connell SE;Montefiori DC;Eaton A;Neuzil KM;Stephens DS;Roberts PC;Beigel JH;DMID 21-0012 Study Group
通讯作者：
DMID 21-0012 Study Group